Fairvalue-Calculator Fairvalue-Calculator
EN DE

Tenaya Therapeutics, Inc (TNYA) Fair Value & Analysis

Healthcare · US · Market cap $158M

Price$0.7309
Fair Value$0.3800
Upside-48.0%
Quality95/100
Evidence: Low Range $0.2500 – $0.4700

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Tenaya Therapeutics, Inc (TNYA) currently trades at $0.7309, while our model-based Fair Value estimate is $0.3800 — implying the stock looks roughly 48.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Tenaya Therapeutics, Inc (TNYA) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.3800 versus a price of $0.7309 — about −48% (overvalued). Model-based estimate, not financial advice.
What is the fair value of TNYA?
Our 21-model fair value for Tenaya Therapeutics, Inc is $0.3800 (as of Jun 25, 2026), built from audited fundamentals. The current price is $0.7309.
What is the quality score of TNYA?
Tenaya Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.